ODN 2216 sodium
Based on 1 publication(s) in Google Scholar
ODN 2216 sodium is a type A CpG oligodeoxynucleotide vaccine adjuvant and a TLR9 agonist. ODN 2216 sodium interacts with TLR9 in the lysosomes of CD4+ T cells and activates feedback-dependent signaling pathways. ODN 2216 sodium induces the production of type I interferons, IL-6 and TGF-β via the IRAK4/IRF7 axis, while increasing intracellular ATP levels. ODN 2216 sodium not only induces the differentiation of CD4+ T cells into anti-inflammatory Th3-like regulatory phenotypes to inhibit autologous proliferation, but also enhances the specific CD8+ T cell-mediated cytotoxicity against Mammaglobin-A in breast cancer cells. ODN 2216 sodium is widely used in studies related to breast cancer and systemic lupus erythematosus.
For research use only. We do not sell to patients.
- Purity: 98.57%
- Molecular Weight:6432 (free acid)
-
Storage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) ODN 2216 sodium
More
Biological Activity
|
TLR9 |
ODN 2216 (sodium) (10 μM; 16 h pre-treatment, 9 days co-culture, 48 h cytotoxicity assay) does not significantly enhance MamA2.1-specific activation of primary HLA-A2+ CD8+ T cells or subsequent MamA-specific cytotoxicity against AU565 breast cancer cells compared to MamA2.1 peptide alone[1].
ODN 2216 (sodium) (3 μM; 24 h) induces TLR9-mediated IFN-α secretion by human PBMCs after 24 hours of incubation at a concentration of 3 μM[2].
ODN 2216 (sodium) (0.5-10 μM; 4 days) dose-dependently increases intracellular ATP and IL-6 levels in human PBMCs[2].
ODN 2216 (sodium) (500 ng/mL; 14 hours) physically interacts with intracellular TLR9 in lysosomes of human CD4+ CD25- T cells following 14-hour incubation with 500 ng/mL ODN 2216 FITC[3].
ODN 2216 (sodium) (500 ng/mL; 72 hours) induced increased proliferation of human CD4+ CD25- T cells, which is dependent on TLR9 signaling via TLR9, MyD88, IRAK1, and TRAF3, but not IRF7[3].
ODN 2216 (sodium) (500 ng/mL; 48 hours) treated human CD4+ CD25- T cells acquire dose-dependent suppressive activity against untreated autologous CD4+ T cells, with maximum suppression (48.57%) at a 4:1 suppressor:responder ratio[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MamA2.1-specific activation of primary HLA-A2+ CD8+ T cells or subsequent MamA-specific cytotoxicity against AU565 breast cancer cells
-
Concentration:10 µM
-
Incubation Time:16 h pre-treatment, 9 days co-culture, 48 h cytotoxicity assay
-
Result:Couldn't significantly enhance MamA2.1-specific activation of primary HLA-A2+ CD8+ T cells or subsequent MamA-specific cytotoxicity against AU565 breast cancer cells compared to MamA2.1 peptide alone.
-
Cell Line:human PBMC
-
Concentration:0.5, 1, 5, 10 μM
-
Incubation Time:4 days
-
Result:Dose-dependently increased intracellular ATP levels and IL-6 secretion in human PBMCs.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HLA-A2/C57BL/6J transgenic mice; SCID/beige mice (vaccinated with MamA2.1 peptide, adoptive CD8+ T cell transfer, orthotopically implanted 24-day old AU565 breast tumors)[1]
-
Dosage:100 µg/mouse
-
Administration:i.p.; 4 total doses at 2-week intervals
-
Result:Demonstrated significantly enhanced IL-12p70 mRNA expression in peritoneal macrophages compared to MamA2.1 peptide alone groups.
Demonstrated significantly enhanced TLR9 mRNA expression in peritoneal macrophages compared to MamA2.1 peptide alone groups.
Demonstrated significantly enhanced TLR6 mRNA expression in peritoneal macrophages compared to MamA2.1 peptide alone groups.
Induced significantly enhanced MamA2.1 tetramer staining in CD8+ T cells compared to no peptide or MamA2.1 peptide alone groups.
Did not result in a significant reduction in tumor growth in SCID/beige mice following adoptive T cell transfer compared to MamA2.1 peptide alone groups.
Chemical Information
-
Appearance Solid
-
Molecular Weight 6432 (free acid)
-
Color White to off-white
-
SMILES
[ODN 2216 (sodium)]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Polyamine metabolism controls B-to-Z DNA transition to orchestrate DNA sensor cGAS activity. [Abstract]2023 Nov 14;56(11):2508-2522.e6. PMID: 37848037
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2242 KB)
References
[1]. Babaer D, et al. Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells. Cancers (Basel). 2019;11(5):672. Published 2019 May 14. [Content Brief]
[2]. Römmler F, et al. Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. PLoS One. 2015;10(2):e0116703. Published 2015 Feb 19. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz